A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Key facts
- Where
- Al-Ahsa, Dammam, Jeddah és Riyadh, Szaúd-ArábiaSee the 10 sites
- Phase
- 3. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Forrás: NCT07613307: ki vehet részt
Where in Szaúd-Arábia
- King Abdulaziz University for Health Sciences Ministry of National Guard Health AffairsAl-Ahsa, Szaúd-ArábiaToborzás még nem indult
- Imam Abdulrahman bin Faisal UniversityDammam, Szaúd-ArábiaTaking people
- King Fahad Specialist HospitalDammam, Szaúd-ArábiaTaking people
- Dr. Soliman Fakeeh HospitalJeddah, Szaúd-ArábiaTaking people
- King Abdulaziz University HospitalJeddah, Szaúd-ArábiaTaking people
- King Fahad Armed Forces Hospital JeddahJeddah, Szaúd-ArábiaToborzás még nem indult
- National Guard Health Affairs: King Abdulaziz Medical CityJeddah, Szaúd-ArábiaToborzás még nem indult
- Dr. Soliman Fakeeh HospitalRiyadh, Szaúd-ArábiaToborzás még nem indult
- King Saud University Medical CityRiyadh, Szaúd-ArábiaTaking people
- Osepdale Fatebenefratelli e OftalmicoRiyadh, Szaúd-ArábiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07613307
- Record updated
- 2026. október 8.
- Original description
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.Read full original descriptionShow less
A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.
Inclusion: Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards; Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol/mol)) to less than 9.5% (91 mmol/mol) at screening; Intend to be compliant with the fast during the Ramadan period; Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening; Have body mass index (BMI) of 25 kilograms per meter square (kg/m2) or higher at screening.
Exclusion: Have a history of chronic or acute pancreatitis any time prior to screening; Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes; Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years; Have a history of cholecystectomy (surgically removed gallbladder); Have New York Heart Association Functional Classification IV congestive heart-failure; Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator.